Leitlinien zur Sklerosierungsbehandlung der Varikose^[*] (ICD 10: I83.0, I83.1, I83.2, I83.9) Entwicklungsstufe 1

 

 Buy Article Permissions and Reprints

^* Diese Leitlinie wurde im Auftrag der Deutschen Gesellschaft für Phlebologie (DGP) ausgearbeitet, vom Vorstand und im wissenschaftlichen Beirat der DGP am 15. Juni 2001 verabschiedet und am 12. Mai 2003 novelliert. Diese Leitlinie berücksichtigt den aktuellen Stand der Literatur, aber nicht die in jedem Fall unterschiedliche Zulassungsbestimmungen für die verschiedenen Pharmaka.

• Literatur

• 1 Baccaglini U, Spreafico G, Castoro C, Sorrentino P. Consensus Conference on Sclerotherapy or Varicose Veins of the Lower Limbs. Phlebology 1997; 12: 2-16.
  CrossrefGoogle Scholar
• 2 Baccaglini U, Stemmer R, Partsch U. Internationale Fragebogenaktion zur Praxis der Verödungsbehandlung. Phlebologie 1997; 26: 129-42.
  Google Scholar
• 3 Benigni JP, Sadoun S, Thirion V, Sica M, Demagny Y, Chahim M. Télangictasies et varices réticulaires Traitement par la mousse d’Aetoxisclérol á 0,25%. Présentation d’une étude pilote. Phlébologie 1999; 52: 283-90.
  Google Scholar
• 4 Bergan JJ, Weiss RA, Goldman MP. Extensive tissue necrosis following high concentration sclerotherapy for varicose veins. Dermatol Surg 2000; 26: 535-42.
  CrossrefPubMedGoogle Scholar
• 5 Cavezzi A, Frullini A. Echosclerotherapy in the short saphenous vein insufficiency: personal experience. Abstract UIP, Sydney 1998.
  Google Scholar
• 6 Cavezzi A, Frullini A. Il ruola della mousse sclerosante nella ecosclerosi safenica e delle varici recidive. Esperienza personale. Flebologia 1998; 9: 1-3.
  Google Scholar
• 7 Conrad P, Malouf GM, Stacey MC. The Australian Polidocanol (Aethoxysklerol) Study. Results at 1 year. Phlebology 1994; 9: 17-20.
  CrossrefGoogle Scholar
• 8 Conrad P, Malouf GM, Stacey MC. The Australian Polidocanol (Aethoxysklerol) study. Results at 2 years. Dermatol Surg 1995; 21: 334-6.
  PubMedGoogle Scholar
• 9 Drake LA, Dinehart SM, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, Skouge JW, Webster SB, Whitaker DC, Butler B, Lowery BJ. Guidelines of care for sclerotherapy treatment of varicose and teleangiectatic leg veins. J Am Acad Dermatol 1996; 34: 523-8.
  CrossrefPubMedGoogle Scholar
• 10 Dover J, Sadick N, Goldman MP. The role of lasers and light sources in the treatment of leg veins. Derm Surg 1999; 25: 328-36.
  CrossrefPubMedGoogle Scholar
• 11 Einarsson E, Eklöf B, Neglén P. Sclerotherapy or Surgery as Treatment for Varicose Veins:A Prospective Randomized Study. Phlebology 1993; 8: 22-6.
  CrossrefGoogle Scholar
• 12 Fegan WG. Continous compression technique of infecting varicose veins. Lancet 1963; 109-12.
  PubMedGoogle Scholar
• 13 Feied CF. Deep vein thrombosis: the risks of sclerotherapy in hypercoagulable states. Sem Dermatol 1993; 12: 135-49.
  Google Scholar
• 14 Feied CF, Jackson JJ, Bren TS, Bond OB, Fernando CE, Young VC, Hashemiyoon RB. Allergic reactions to polidocanol for vein sclerosis. J Dermatol Surg Oncol 1994; 20: 466-8.
  CrossrefPubMedGoogle Scholar
• 15 Feuerstein W. Schwere anaphylaktische Reaktion auf Hydroxypolyaethoxydodecan. VASA 1973; 3: 292-4.
  Google Scholar
• 16 Fisher DA. Regarding extensive tissue necrosis following high concentration sclerotherapy for varicose veins. Dermatol Surg 2000; 26: 1081.
  PubMedGoogle Scholar
• 17 Flückiger P. Nicht-operative retrograde Varizenverödung mit Varisylschaum. Schweiz Med Wochenschr 1956; 48: 1368-70.
  Google Scholar
• 18 Frullini A, Cavezzi A. Ultrasound guided sclerotherapy in the treatment of long saphenaous vein insufficiency. Vasomed 1999; 11 (Suppl 1): 8.
  Google Scholar
• 19 Frullini A. Sclerosing foam in the treatment of recurrent varicose veins. In: Henriet JP. (ed). Foam sclerotherapy state of the art. Editions Phlebologiques Francaises; 2001: 73-8.
  Google Scholar
• 20 Georgiev M. Postsclerotherapy hyperpigmentations. J Dermatol Surg Oncol 1993; 19: 649-52.
  CrossrefPubMedGoogle Scholar
• 21 Geukens J, Rabe E, Bieber T. Embolia cutis medicamentosa of the foot after sclerotherapy. Eur J Dermatol 1999; 9: 132-3.
  PubMedGoogle Scholar
• 22 Gobin JP. The sclerotherapy position in recurrent varicose veins treatment. Int Angiology 20 2 (Suppl 1) 336 14.
  Google Scholar
• 23 Goldman PM. Polidocanol (Aethoxysklerol) for sclerotherapy of superficial venules and telangiectasias. J Dermatol Surg Oncol 1989; 15: 204-9.
  CrossrefPubMedGoogle Scholar
• 24 Goldman PM, Beaudoing D, Marley W, Lopez L, Butie A. Compression in the treatment of leg teleangiectasia: a preliminary report. J Dermatol Surg Oncol 1990; 16: 322-5.
  CrossrefPubMedGoogle Scholar
• 25 Goldman PM, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting and hyperpigmentation following sclerotherapy. Dermatol Surg 1995; 21: 19-29.
  CrossrefPubMedGoogle Scholar
• 26 Goldmann PM. Complications of sclerotherapy. In: Gloviczki P, Yao J. (eds). Handbook of venous disorders. London: Chapmann & Hall Medical; 1996: 374-93
  Google Scholar
• 27 Grondin L, Young R, Wouters L. Sclérothérapie ècho-guidée et sécurité: Comparison des techniques. Phlebologie 1997; 50: 241-5.
  Google Scholar
• 28 Guex JJ. Ultrasound guided sclerotherapy (USGS) for perforating veins. Hawaii Med J 2000; 59: 261-2.
  PubMedGoogle Scholar
• 29 Härtel SL. Fünf-Jahres-Nachuntersuchungsergebnisse der Sklerosierungstherapie nach Stemmer bei 118 Patienten mit primärer Varikosis. Vasomed 1998; 4: 272-3.
  Google Scholar
• 30 Hamel-Desnos C, Desnos P, Ouvry P. Nouveautés thérapeutiques dans la prise en charge de la maladie variqueuse: écho-sclérothérapie et mousse. Phlébologie 2003; 56: 41.
  Google Scholar
• 31 Henriet JP. One year experience with sclerotherapy of reticular veins and telangiectases using polidocanol foam in daily routine: feasibility results, complications. Phlébologie 1997; 50: 355-60.
  Google Scholar
• 32 Hohlbaum G. Über iatrogene Schäden bei der Varizensklerosierung. In: Staubesand J, Schöpf E. (Hrsg). Neuere Aspekte der Sklerosierungstherapie. Berlin, Heidelberg, New York: Springer; 1990: 70-81
  CrossrefGoogle Scholar
• 33 Hübner K. Ambulante Therapie der Stammvarikose mittels Krossektomie und Sklerotherapie – ein Beitrag aus der Praxis des niedergelassenen Phlebologen. Phlebologie 1991; 20: 104-8.
  Google Scholar
• 34 Kersting E, Hornschuh B, Bröcker E-B. Embolia cutis medicamentosa nach Varizensklerosierung mit Polidocanol. Phlebologie 1998; 27: 55-7.
  Article in Thieme ConnectGoogle Scholar
• 35 Kreussler.. Aethoxysklerol-Fachinformation der Herstellerfirma, Chemische Fabrik Kreussler & Co GmbH, Stand 2/1996.
  Google Scholar
• 36 Malouf GM. Ambulatory venous surgery versus sclerotherapy. Hawaii Med J 2000; 59: 248-9.
  PubMedGoogle Scholar
• 37 Massay RA. Regarding the use of compression stockings after sclerotherapy. Dermatol Surg 1999; 25: 517.
  PubMedGoogle Scholar
• 38 Mayer H, Brücke H. Zur Ätiologie und Behandlung der Varizen der unteren Extremität. Chir Praxis 1957; 4: 521-8.
  Google Scholar
• 39 McCoy S, Evans A, Spurrier N. Sclerotherapy for leg telangiectasia – a blinded comparative trial of polidocanol and hypertonic saline. Dermatol Surg 1999; 25: 381-6.
  CrossrefPubMedGoogle Scholar
• 40 McDonagh B. Comments on the use of post-sclerotherapy compression. Dermatol Surg 1999; 25: 519-21.
  PubMedGoogle Scholar
• 41 Monfreux A. Traitement sclérosant des troncs saphèniens et leurs collatèrales de gros calibre par la méthode mus. Phlébologie 1997; 50: 351-3.
  Google Scholar
• 42 Norris MJ, Carlin MC, Ratz JL. Treatment of essential telangiectasia: Effects of increasing concentrations of polidocanol. J Am Acad of Dermatol 1989; 20: 643-9.
  CrossrefPubMedGoogle Scholar
• 43 Oesch A, Stirnemann P, Mahler F. The acute ischemic syndrome of the foot after sclerotherapy of varicose veins. Schweiz Med Wochenschr 1984; 114: 1155-8.
  PubMedGoogle Scholar
• 44 Pradalier A, Vincent D, Hentschel V, Cohen-Jonathan AM, Daniel E. Allergie aux sclérosants des varices. Rev Fr Allergol 1995; 35: 440-3.
  Google Scholar
• 45 Rabe E. (Hrsg). Grundlagen der Phlebologie. 2. Auflage. Köln: Viavital; 2000
  PubMedGoogle Scholar
• 46 Reddy P, Wickers J, Terry T, Lamont P, Moller J, Dormandy JA. What is the correct period of bandaging following sclerotherapy?. Phlebology 1986; 1: 217-20.
  CrossrefGoogle Scholar
• 47 Remy W, Vogt H-J, Borelli S. Embolia cutis medicamentosa-artige Hautnekrosen nach Sklerosierungsbehandlung. Phlebol Proktol 1978; 7: 67-72.
  Google Scholar
• 48 Sadoun S, Benigni JP. La mousse de sclerosant: etat de l’art. In: Rabe E. et al. (Hrsg). Phlebology ’99. Köln: Viavital; 1999: 146.
  Google Scholar
• 49 Seydewitz V, Staubesand J. Das ultrastrukturelle Substrat der Wirkung paravasal und intraarteriell applizierter Sklerosierungsmittel: Ein experimenteller Beitrag zum Problem iatrogener Schäden nach Sklerotherapie. In: Staubesand J, Schöpf E. (Hrsg). Neuere Aspekte der Sklerosierungstherapie. Heidelberg: Springer; 1990: 40-65
  CrossrefGoogle Scholar
• 50 Sigg K. Neuere Gesichtspunkte zur Technik der Varizenbehandlung. Ther Umschau 1949; 6: 127-34.
  Google Scholar
• 51 Schadeck M. Duplex-kontrollierte Sklerosierungsbehandlung der Vena saphena magna. Phlebologie 1996; 25: 78-82.
  Google Scholar
• 52 Schadeck M, Allaert FA. Résultats à long terme de la sclérothérapie des saphènes internes. Phlébologie 1997; 50: 257-62.
  Google Scholar
• 53 Schadeck M. Echo-sclerotherapy. Phlébologie 1999; 52 special issue 10 103-6.
  Google Scholar
• 54 Schultz-Ehrenburg U, Tourbier H. Dopplerkontrollierte Verödungsbehandlung der Vena saphena magna. Phlebol Proktol 1984; 13: 117-22.
  Google Scholar
• 55 Stanley PRW, Bickerton DR, Campbell WB. Injection sclerotherapy for varicose veins – a comparison of materials for applying local compression. Phlebology 1991; 6: 37-9.
  CrossrefGoogle Scholar
• 56 Tazelaar DJ, Neumann HAM, de Roos KP. Long cotton wool rolls as compression enhancers in macrosclerotherapy for varicose veins. Dermatol Surg 1999; 25: 38-40.
  CrossrefPubMedGoogle Scholar
• 57 Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg 2001; 27: 58-60.
  PubMedGoogle Scholar
• 58 Tessari L. Nouvelle technique d’obtention de la sclèro-mousse. Phlébologie 2000; 53: 129.
  Google Scholar
• 59 Van der Plas JPL, Lambers JC, van Wersch JW, Koehler PJ. Reversible ischaemic neurological deficit after sclerotherapy of varicose veins. Lancet 1994; 343: 428.
  PubMedGoogle Scholar
• 60 Villavicencio J, Pfeifer J, Lohr J, Goldman M, Cranley R, Spence R. Sclerotherapy for varicose veins: Practice guidelines and sclerotherapy procedures. In: Glovicki P, Yao J. (eds). Handbook of venous disorders. London: Chapmann & Hall Medical; 1996: 337-54
  Google Scholar
• 61 Vin F. Principes de la sclérothéraphie des troncs saphènes internes. Phlébologie 1997; 50: 229-34.
  Google Scholar
• 62 Weiss RA, Weiss MA. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonics saline vs. polido-canol. J Dermatol Surg Oncol 1990; 16: 800-4.
  CrossrefPubMedGoogle Scholar
• 63 Weiss RA, Sadick NS, Goldman MP, Weiss MA. Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome. Dermatol Surg 1999; 25: 105-8.
  CrossrefPubMedGoogle Scholar
• 64 Wenner L. Improvement of immediate and longterm results in sclerotherapy. VASA 1986; 15: 180-3.
  Google Scholar
• 65 Wollmann JC. Schaum – zwischen Vergangenheit und Zukunft. Vasomed 2002; 16: 34-8.
  Google Scholar
• 66 Yamaki T, Nozaki M, Sasaki K. Color duplex-guided sclerotherapy for the treatment of venous malformations. Dermatol Surg 2000; 26: 323-8.
  CrossrefPubMedGoogle Scholar
• 67 Yamaki T, Nozaki M, Fujiwara O, Yoshida E. Duplex- guided foam sclerotherapy for the treatment of the symptomatic venous malformations of the face. Dermatol Surg 2002; 28: 619-22.
  PubMedGoogle Scholar